News

(Bloomberg) -- Sign up for the India Edition newsletter by Menaka Doshi – an insider's guide to the emerging economic powerhouse, and the billionaires and businesses behind its rise, delivered weekly.Most Read from BloombergCan Portland Turn a Corner?Why American Mobility Ground to a HaltSpaceX Bid to Turn Texas Starbase Into City Is Set for Vote in MaySaudi Arabia’s Neom Signs $5 Billion Deal for AI Data CenterCutting Arena Subsidies Can Help Cover Tax Cuts, Think Tank SaysCanva Inc. is taking

Personal care company Nu Skin (NYSE:NUS) reported Q4 CY2024 results topping the market’s revenue expectations, but sales fell by 8.8% year on year to $445.6 million. On the other hand, next quarter’s revenue guidance of $355 million was less impressive, coming in 12.3% below analysts’ estimates. Its non-GAAP profit of $0.38 per share was 72.3% above analysts’ consensus estimates.

Dialysis provider DaVita Inc. (NYSE:DVA) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.7% year on year to $3.29 billion. Its non-GAAP profit of $2.24 per share was 4.3% above analysts’ consensus estimates.

Genomics company Pacific Biosciences of California (NASDAQ:PACB) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 32.8% year on year to $39.22 million. Its non-GAAP loss of $0.20 per share was 15.5% below analysts’ consensus estimates.

Construction management software maker Procore (NYSE:PCOR) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 16.2% year on year to $302 million. The company expects next quarter’s revenue to be around $302 million, close to analysts’ estimates. Its non-GAAP profit of $0.01 per share was 91.2% below analysts’ consensus estimates.

Acoustic component provider Knowles (NYSE:KN) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 33.8% year on year to $142.5 million. Next quarter’s revenue guidance of $129 million underwhelmed, coming in 5.5% below analysts’ estimates. Its non-GAAP profit of $0.27 per share was 4.4% below analysts’ consensus estimates.

Shares of Palantir Technologies hit a record closing price again Thursday and are up more than 50% to start 2025, growth that analysts attribute in part to the stock’s popularity with retail investors.